Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells

Li, Huangcan; Feng, Zhuoying; He, Ming

doi:10.7150/thno.41388

Cited by 110 publications

(97 citation statements)

References 208 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various inhibitors of OXPHOS activity of GSCs have been described as well [ 12 , 13 , 17 , 18 , 20 , 63 , 73 ] ( Table 2 ).…”

Section: Energy Metabolism In Idh1wt Gscsmentioning

confidence: 99%

“…It has become generally accepted that more differentiated (i.e., non-CSC) proliferating cancer cells preferentially use aerobic glycolysis for their ATP production, whereas CSCs preferentially use OXPHOS [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ]. Similar to healthy cells, CSCs benefit from low levels of ROS, but not excess levels of ROS, which are toxic [ 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, it is crucial to determine whether quiescent GSCs can be effectively and specifically treated therapeutically with metabolic stressors or inhibitors affecting the energy metabolism in mitochondria. Inhibitors of mitochondrial metabolism for the therapeutic targeting of CSCs have been reviewed recently [ 12 , 13 , 17 , 18 , 20 , 38 , 39 ]. It has to be stressed here that the inhibition of aerobic glycolysis, which is a hallmark of cancer [ 37 ], in differentiated proliferating glioblastoma cells is not an option for treating glioblastoma patients because clinical trials have thus far shown that potential drugs targeting glycolysis are either not well tolerated or had no clinical efficacy [ 18 , 38 , 40 , 41 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?

Noorden

Hira

Dijck

et al. 2021

Cells

View full text Add to dashboard Cite

Cancer is a redox disease. Low levels of reactive oxygen species (ROS) are beneficial for cells and have anti-cancer effects. ROS are produced in the mitochondria during ATP production by oxidative phosphorylation (OXPHOS). In the present review, we describe ATP production in primary brain tumors, glioblastoma, in relation to ROS production. Differentiated glioblastoma cells mainly use glycolysis for ATP production (aerobic glycolysis) without ROS production, whereas glioblastoma stem cells (GSCs) in hypoxic periarteriolar niches use OXPHOS for ATP and ROS production, which is modest because of the hypoxia and quiescence of GSCs. In a significant proportion of glioblastoma, isocitrate dehydrogenase 1 (IDH1) is mutated, causing metabolic rewiring, and all cancer cells use OXPHOS for ATP and ROS production. Systemic therapeutic inhibition of glycolysis is not an option as clinical trials have shown ineffectiveness or unwanted side effects. We argue that systemic therapeutic inhibition of OXPHOS is not an option either because the anti-cancer effects of ROS production in healthy cells is inhibited as well. Therefore, we advocate to remove GSCs out of their hypoxic niches by the inhibition of their binding to niches to enable their differentiation and thus increase their sensitivity to radiotherapy and/or chemotherapy.

show abstract

“…Various inhibitors of OXPHOS activity of GSCs have been described as well [ 12 , 13 , 17 , 18 , 20 , 63 , 73 ] ( Table 2 ).…”

Section: Energy Metabolism In Idh1wt Gscsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?

Noorden

Hira

Dijck

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…CSCs are also the main source of cancer relapse. Interestingly, lipid metabolic reprogramming contributes to CSCs expansion and survival therefore enhancing the occurrence of chemoresistance [ 85 ]. Several lipogenic genes are reprogrammed in CSCs and are critical for CSCs maintenance.…”

Section: Changes In Lipid Metabolism Contribute To Anticancer Drugmentioning

confidence: 99%

Lipid Metabolism and Resistance to Anticancer Treatment

Germain

Dhayer

Boileau

et al. 2020

Biology

View full text Add to dashboard Cite

Metabolic reprogramming is crucial to respond to cancer cell requirements during tumor development. In the last decade, metabolic alterations have been shown to modulate cancer cells’ sensitivity to chemotherapeutic agents including conventional and targeted therapies. Recently, it became apparent that changes in lipid metabolism represent important mediators of resistance to anticancer agents. In this review, we highlight changes in lipid metabolism associated with therapy resistance, their significance and how dysregulated lipid metabolism could be exploited to overcome anticancer drug resistance.

show abstract

“…Furthermore, lipid metabolic reprogramming contributes to the chemotherapy resistance by a number of mechanisms (for review, see [ 56 ]). It diminishes the oxidative stress elicited by anticancer therapeutics [ 57 , 58 ], interferes with drug-induced cell death [ 59 ], and favors the production of drug-resistant cancer stem cells [ 60 ]. Thus, lipid metabolic reprogramming contributes to the metabolic flexibility that is adapted by cancer cells to fulfill the energy requirement required for proliferation and survival.…”

Section: Specific Metabolic Alterations In Malignant Cellsmentioning

confidence: 99%

Linking Metabolic Reprogramming, Plasticity and Tumor Progression

Shuvalov

Daks

Fedorova

et al. 2021

Cancers

View full text Add to dashboard Cite

The specific molecular features of cancer cells that distinguish them from the normal ones are denoted as “hallmarks of cancer”. One of the critical hallmarks of cancer is an altered metabolism which provides tumor cells with energy and structural resources necessary for rapid proliferation. The key feature of a cancer-reprogrammed metabolism is its plasticity, allowing cancer cells to better adapt to various conditions and to oppose different therapies. Furthermore, the alterations of metabolic pathways in malignant cells are heterogeneous and are defined by several factors including the tissue of origin, driving mutations, and microenvironment. In the present review, we discuss the key features of metabolic reprogramming and plasticity associated with different stages of tumor, from primary tumors to metastases. We also provide evidence of the successful usage of metabolic drugs in anticancer therapy. Finally, we highlight new promising targets for the development of new metabolic drugs.

show abstract

Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells

Cited by 110 publications

References 208 publications

Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?

Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?

Lipid Metabolism and Resistance to Anticancer Treatment

Linking Metabolic Reprogramming, Plasticity and Tumor Progression

Contact Info

Product

Resources

About